Page last updated: 2024-10-18

dalteparin and Leukemia

dalteparin has been researched along with Leukemia in 2 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chojnowski, K1
TreliƄski, J1
Wawrzyniak, E1
Robak, T1
Vignoli, A1
Marchetti, M1
Russo, L1
Cantalino, E1
Diani, E1
Bonacina, G1
Falanga, A1

Trials

1 trial available for dalteparin and Leukemia

ArticleYear
The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:5

    Topics: Acute Disease; Anticoagulants; Blood Coagulation; Disseminated Intravascular Coagulation; Humans; Le

2002

Other Studies

1 other study available for dalteparin and Leukemia

ArticleYear
LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.
    Cancer investigation, 2011, Volume: 29, Issue:2

    Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Fibroblast G

2011